Loading…
QNTM
Quantum Biopharma Ltd.
NASDAQ· Healthcare· Biotechnology· CUSIP 74764Y205
$3.08-1.76%Price as of Aug 29, 18:47 UTC · updated once a day, after the close
Key metrics
- Market cap
- $19.77M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.9x
- Dividend yield
- —
- Payout
- —
- EPS
- -$4.49
- ROE
- -621.46%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.43
- 52-week high
- $21.00
- 52-week low
- $2.07
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -95.7% over 5Y.
today you would have $37.49▼ -96.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $7.30 | $3.68 | $59.80 | $51.22 | |
| P/B | 1.9x | 4.1x | 0.7x | 2.7x | 1.0x |
| EPS | -$8.20 | -$13.12 | -$29.93 | -$39.61 | |
| ROE | -129.48% | -378.01% | -123.71% | -135.25% | -77.29% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CMMBChemomab Therapeutics Ltd. | $2.71 | — | 2.3x | — | -82.17% | $19.86M |
| NEUPNeuphoria Therapeutics Inc. | $3.76 | — | 0.7x | — | -62.90% | $20.32M |
| CCMConcord Medical Services Holdings Ltd | $4.76 | — | — | — | -21.88% | $20.67M |
| AKTXAkari Therapeutics Plc | $10.70 |
About the company
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.
- Toronto, Canada
Company description provided by Yahoo Finance.